NCT00317720 2025-04-30
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
14 trialsNCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT00810017 2022-05-19
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT00297596 2021-10-28
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02139358 2021-02-04
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT00428922 2018-08-09
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00201760 2017-12-27
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT01048099 2016-01-29
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase NA Completed
NCT00426556 2015-12-28
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Novartis
Phase 1 Completed